http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Ajer+Jeffrey+Robert/26727973.html si-local-file:///var/storage/secattach/20260702/26727973.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Ajer+Jeffrey+Robert/26727973.html Thu, 02 Jul 2026 16:16:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Ajer+Jeffrey+Robert/26727973.html si-local-file:///var/storage/secattach/20260702/26727973.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Ajer+Jeffrey+Robert/26727973.html Thu, 02 Jul 2026 16:16:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+CAIN+CHRISTOPHER+W./26727976.html si-local-file:///var/storage/secattach/20260702/26727976.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+CAIN+CHRISTOPHER+W./26727976.html Thu, 02 Jul 2026 16:16:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+CAIN+CHRISTOPHER+W./26727976.html si-local-file:///var/storage/secattach/20260702/26727976.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+CAIN+CHRISTOPHER+W./26727976.html Thu, 02 Jul 2026 16:16:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Kiselak+Tomas/26727941.html si-local-file:///var/storage/secattach/20260702/26727941.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Kiselak+Tomas/26727941.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Kiselak+Tomas/26727941.html si-local-file:///var/storage/secattach/20260702/26727941.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Kiselak+Tomas/26727941.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Morris+Arlene/26727947.html si-local-file:///var/storage/secattach/20260702/26727947.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Morris+Arlene/26727947.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Morris+Arlene/26727947.html si-local-file:///var/storage/secattach/20260702/26727947.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Morris+Arlene/26727947.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Moses+Jennifer+K./26727958.html si-local-file:///var/storage/secattach/20260702/26727958.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Moses+Jennifer+K./26727958.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Moses+Jennifer+K./26727958.html si-local-file:///var/storage/secattach/20260702/26727958.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Moses+Jennifer+K./26727958.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727960.html si-local-file:///var/storage/secattach/20260702/26727960.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727960.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727960.html si-local-file:///var/storage/secattach/20260702/26727960.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+Jul+01++Filed+by%3A+Gheuens+Sarah/26727960.html Thu, 02 Jul 2026 16:15:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2435+at+RBC+Capital/26709300.html RBC Capital analyst Lisa Walter raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $35.00 (from $34.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2435+at+RBC+Capital/26709300.html Tue, 30 Jun 2026 06:48:57 -0400 VRDN http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2443+at+Wedbush/26704577.html <p>Wedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.</p><p>The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price per course of treatment will be $450,000 (for a 75kg patient). This is estimated to be at parity vs. Tepezza based on a Tepezza vial WAC price of ~$18,500. After updating our Lumvoa pricing in our model and incorporating the raise in May, our VRDN target increases to $43/ share (prior $32). We anticipate limited payer http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2443+at+Wedbush/26704577.html Mon, 29 Jun 2026 12:25:28 -0400 VRDN http://www.streetinsider.com/Analyst+Comments/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2443+at+Wedbush/26704577.html <p>Wedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.</p><p>The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price per course of treatment will be $450,000 (for a 75kg patient). This is estimated to be at parity vs. Tepezza based on a Tepezza vial WAC price of ~$18,500. After updating our Lumvoa pricing in our model and incorporating the raise in May, our VRDN target increases to $43/ share (prior $32). We anticipate limited payer http://www.streetinsider.com/Analyst+Comments/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2443+at+Wedbush/26704577.html Mon, 29 Jun 2026 12:25:28 -0400 VRDN http://www.streetinsider.com/Hot+Comments/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2443+at+Wedbush/26704577.html <p>Wedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.</p><p>The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price per course of treatment will be $450,000 (for a 75kg patient). This is estimated to be at parity vs. Tepezza based on a Tepezza vial WAC price of ~$18,500. After updating our Lumvoa pricing in our model and incorporating the raise in May, our VRDN target increases to $43/ share (prior $32). We anticipate limited payer http://www.streetinsider.com/Hot+Comments/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2443+at+Wedbush/26704577.html Mon, 29 Jun 2026 12:25:28 -0400 VRDN http://www.streetinsider.com/Analyst+Comments/William+Blair+on+Viridian+Therapeutic+%28VRDN%29%3A+%27We+came+away+from+the+call+incrementally+more+confident%27/26704575.html <p>William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)</p><p>The analyst comments "On Monday, June 29, Viridian hosted a call to discuss the approval and commercial launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). Management discussed the strength of Lumvoa’s FDA label, market opportunity and commercial strategy, progress on launch readiness, and expectations for the launch and adoption. We came away from the call incrementally more confident in the company’s commercial readiness and the long-term opportunity for Lumvoa."</p><p>For an analyst ratings summary and ratings history on Viridian Therapeutic <a href="http://www.streetinsider.com/rating_history.php?q=VRDN">click here</a>. For http://www.streetinsider.com/Analyst+Comments/William+Blair+on+Viridian+Therapeutic+%28VRDN%29%3A+%27We+came+away+from+the+call+incrementally+more+confident%27/26704575.html Mon, 29 Jun 2026 12:25:00 -0400 VRDN http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Press+Releases/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html <p>DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=aQOc0YN9hLEiY8gzocaZsNgBhcfDeK0VJP4DhglSHMOa-HXjF1J517DRMv-Iv5V2Uq9WxLauTwfWf0vZuSgycr9YgjqDnvGGJyQ-R0RSfQg=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization.</p> <p><a href="https://www.globenewswire.com/Tracker?data=Uax7tMXKpgs_84TWdlsgIlK8QTXVktAuzDz5Ufnc33zottBl7Y8uhowrmgqvRJ4u09dv_T52EMJniol0fq4yDBgQerCLSsGBlJaOZV96q2TQ0FJb1oIE25aRqm9oMcRO" rel="nofollow" target="_blank"><strong>Universe Pharmaceuticals</strong></a> <strong>(NASDAQ: UPC)</strong> announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.75 million, is expected http://www.streetinsider.com/Globe+Newswire/4+Sizzling+Biotech+and+Healthcare+Companies+Reporting+Strategic+Milestones/26703277.html Mon, 29 Jun 2026 09:50:32 -0400 DCOY UPC VRDN http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2440+at+Stifel/26703273.html Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $39.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Raised+to+%2440+at+Stifel/26703273.html Mon, 29 Jun 2026 09:50:19 -0400 VRDN http://www.streetinsider.com/Upgrades/Wells+Fargo+Upgrades+Viridian+Therapeutic+%28VRDN%29+to+Overweight/26703240.html <p>Wells Fargo analyst Derek Archila upgraded Viridian Therapeutic (NASDAQ: VRDN) from Equal Weight to Overweight with a price target of $31.00.</p><p>For an analyst ratings summary and ratings history on Viridian Therapeutic <a href="http://www.streetinsider.com/rating_history.php?q=VRDN">click here</a>. For more ratings news on Viridian Therapeutic <a href="http://www.streetinsider.com/stock_lookup_news.php?q=VRDN&amp;type=analyst">click here</a>.</p><p>Shares of Viridian Therapeutic closed at $17.90 yesterday.</p> http://www.streetinsider.com/Upgrades/Wells+Fargo+Upgrades+Viridian+Therapeutic+%28VRDN%29+to+Overweight/26703240.html Mon, 29 Jun 2026 09:43:21 -0400 VRDN